Patient-Reported Outcomes After Neoadjuvant Therapy and Watch-and-Wait for Rectal Cancer: A Systematic Review and Meta-Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Watch-and-wait (WW) for rectal cancer may reduce bowel symptoms and improve quality of life (QoL) compared to surgery. More research is needed to fully understand patient-reported outcomes (PROs) with WW versus other treatments.
Area Of Science
- Oncology
- Gastroenterology
- Surgical Oncology
Background
- Rectal cancer treatment advancements focus on oncologic outcomes and long-term effects.
- Watch-and-wait (WW) offers organ preservation after neoadjuvant therapy for clinical complete response.
- WW's impact on patient-reported outcomes (PROs) compared to proctectomy is not well understood.
Purpose Of The Study
- To evaluate patient-reported outcomes (PROs) in rectal cancer patients treated with neoadjuvant therapy followed by watch-and-wait (WW).
Main Methods
- Systematic review and meta-analysis of 25 studies (3139 patients) reporting PROs.
- Included patients with stage I-III rectal adenocarcinoma treated with neoadjuvant therapy and WW, proctectomy, or local excision.
- Random-effects model meta-analysis and narrative synthesis were employed.
Main Results
- Meta-analyses showed fewer bowel symptoms and improved quality of life (QoL) in some subscales for WW compared to surgery.
- 14 of 24 QoL comparisons favored WW in some subscales; 10 showed no difference.
- 11 of 24 symptom scale comparisons favored WW; 13 showed no difference.
Conclusions
- WW may avoid permanent ostomy and surgical morbidity.
- More robust data are needed to compare WW PROs with proctectomy or local excision.
- Prioritizing publication of QoL data is crucial for informed shared decision-making.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.